Aarti Drugs Ordered To Shut Down Amines Plant By Gujarat Pollution Control Board

Market snapshot: Aarti Drugs Limited has received a regulatory closure directive from the Gujarat Pollution Control Board (GPCB) regarding its Amines manufacturing operations in Bharuch, Gujarat. The directive, issued under Section 33A of the Water Act, 1974, provides the company 15 days to address highlighted environmental non-compliances before halting activities. While management downplays immediate financial or operational setbacks, the facility serves as a critical backward integration node.

Data Snapshot

• The company's Q4 FY26 consolidated revenue rose to ₹721.1 crore, marking a 6% year-on-year growth.
• Net profit for Q4 FY26 was ₹55.3 crore, reflecting a ≈12% YoY decline (derived: ₹55.3 crore vs ₹62.8 crore in Q4 FY25).
• The Saykha methyl amines facility had ramped up production to nearly 1,000 tons per month as of March 2026.

What's Changed

• The GPCB has mandated the closure of Amines manufacturing operations at the Saykha Industrial Estate, Gujarat.
• Aarti Drugs has a 15-day compliance window starting July 18, 2026, to address observations or completely shut down the facility.

Key Takeaways

• The Saykha unit is a strategic asset for backward integration into methyl amines, supporting Metformin API manufacturing.
• Operations at Aarti Drugs' other 13 manufacturing units remain unhindered and fully operational.
• The company is actively undertaking corrective steps and preparing a formal response to seek revocation of the GPCB order.

SAHI Perspective

The GPCB's directive is a near-term margin risk for Aarti Drugs. The Saykha plant is a pivotal backward integration project that achieved a production rate of nearly 1,000 tons per month by March 2026. Designed to establish 100% self-reliance for Metformin raw materials, any prolonged halt at this facility will force Aarti Drugs to depend on higher-cost external sources, stalling gross margin recovery.

Market Implications

The specialty chemicals and API sector in Gujarat has frequently encountered regulatory bottlenecks due to stringent environmental audits. While the management has assured that there is no immediate operational halt, the news is expected to invite short-term selling pressure as investors price in the possibility of delayed backward integration benefits.

Trading Signals

Market Bias: Bearish

The GPCB closure directive on the critical Saykha Amines backward integration unit creates near-term compliance risks and threatens margin recovery projections, particularly impacting Metformin self-reliance.

Underweight: Pharmaceuticals, Specialty Chemicals

Trigger Factors:

• A formal announcement regarding GPCB's revocation of the closure order.
• Prolongation of compliance issues past the 15-day grace period.
• Q1 FY27 financial results indicating overall gross margin direction.

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian API and pharmaceutical manufacturing sector relies on extensive compliance with GPCB and other state pollution control boards. Facilities located in key industrial clusters like Bharuch, Gujarat, undergo rigorous environmental audits, making timely remediation crucial to avoiding multi-week operational halts.

Key Risks to Watch

• Failure to secure GPCB revocation within the 15-day timeline leading to an active operational shutdown.
• Increased cost of raw material acquisition for Metformin APIs due to reliance on external methyl amines.
• Potential capital expenditure hikes to implement required waste-water treatment modifications.

Recent Developments

Between May 2024 and June 2026, the company's promoter group decreased its total shareholding by 1.27% to 54.43% through market sales. Previously, Aarti Drugs reported a 16% YoY increase in full-year FY26 profit after tax to ₹194.9 crore.

Closing Insight

Securing a swift revocation of the GPCB order within the 15-day window is paramount for Aarti Drugs to safeguard its cost-efficiency targets. Until the compliance issue is formally resolved, the stock is likely to experience regulatory overhead.

High Performance Trading with SAHI.